about
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.Efficacy of conventional immunosuppressive drugs in IBD.Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent.Nanotechnology in the treatment of inflammatory bowel diseases.Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms.Subtypes of chronic gastritis in patients with celiac disease before and after gluten-free diet.The prognostic value of histology in ulcerative colitis in clinical remission with mesalazineMesalazine vanishing time from rectal mucosa following its topical administration.Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen.A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.Mesalazine treatment in organotypic culture of celiac patients: Comparative study with gluten free diet.Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.Two synchronous adenocarcinomas of the small bowel in a patient with undiagnosed Crohn's disease of the terminal ileumEvaluation of Crohn disease activity with magnetic resonance imagingHas infliximab influenced the course and prognosis of acute severe ulcerative colitis?Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatmentSurvival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide studyAnother paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonistSafe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conceptionSuccessful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseasesInfliximab and quality of life in steroid-dependent Crohn's diseaseDevelopment of fistulae in ileo-anal pouch does not necessarily indicate Crohn's diseaseInfliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-upIncreased risk of breast cancer in first-degree relatives of Crohn's disease patients. An IG-IBD studyEarly versus late surgery for ileo-caecal Crohn's diseaseSmall intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel diseaseSeasonal variations in onset of symptoms in Crohn's diseaseCytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapyInfliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open studyFerritin as a simple indicator of iron deficiency in anemic IBD patientsInfliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomyMastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrheaControversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal FibrosisUnmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi ConsensusMetabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free DietCeliac Disease, Gluten-Free Diet, and Metabolic and Liver DisordersTopical Aminosalicylates and Histologic Healing in Ulcerative Colitis
P50
Q34369381-15B19FE8-50F7-47D7-8D11-4CF4ECD6A204Q34529411-6216B951-D782-4E39-B8FE-144CCAA4B05DQ35967090-62108BE5-BD92-47DC-B5A5-23983BEE5A37Q36127192-97E03B1C-362B-480F-828D-0F9671619FB3Q36350023-03DAE8CD-9E5A-4D96-A68D-BA17B395231DQ38200842-FD5902AB-9786-45B5-A7D1-F871740D6092Q41693622-17BA6ABC-C8C8-49F9-87B9-E9313EF7EDA2Q42284222-4C394382-E9EE-4E28-B917-B510F7BD6794Q42375644-3D994948-C43C-4F50-9E25-53A7A58FAF9AQ42788699-88C476B9-CB32-42AB-B76B-C26C5AB180BCQ45176645-17A29667-4233-4557-A6D1-6378DB1EF918Q46469247-FC7834F2-5B48-4497-98F2-07B19C2F9299Q47654290-C037731F-913A-44A4-884D-B6D434EBE0BAQ51036673-1B7B338B-6E19-4FEE-A782-588E8492177CQ53899790-4AB4ED23-AB2C-4861-8332-2B7059787F66Q57647787-031FF353-DAC2-4499-A9D2-E5D3A1A32C21Q61814334-158405FB-D346-4AC5-9E43-7BF626946D03Q64062261-66155A2B-2AB3-416C-80BA-EB306680568BQ73204666-67F9173F-9788-4789-AB3C-B3FD2298ED87Q77474250-F8EF4749-31DA-4523-B34D-43E10633DEE4Q80045358-71DA7D9C-8274-470A-BEF7-516843BBCCB8Q80123960-9C00317F-7DAE-475D-858F-AD444F56A11FQ80348591-4DC7CFFE-CBEA-4291-B5D8-3D8695BBF521Q80502862-168CD489-12F1-4363-9C1B-FE1DA292A179Q80787250-3A6BE50A-19A2-4D81-A0B1-17681ABE619EQ80793210-9F62F415-0AB2-42DD-913D-F1FEDCD45821Q81230817-9EBB4015-A6BE-49C7-A10E-E8D4285A6750Q81233664-7842148B-737A-4CFC-951C-1D74362A3825Q81334202-81F15839-9A95-4F17-8F42-613BC5EF58A7Q81484642-AD81A8D9-A92B-4EAA-84AF-B4C54B7536BAQ81611327-98A87F0E-080F-49FA-9E0B-AED1B0A8B17DQ81734312-63E1916C-D3D9-4EBC-BC61-AA732DCFFC49Q82350405-9ABE1F52-D272-4590-B27F-031315426FE7Q87181170-7D31F848-2F3C-43DA-A252-76B05D2275F1Q87951656-52A9A6CE-F71D-4B8B-A3B7-D2D36C44B7FDQ89986846-F783BB45-4392-4AC8-A214-A3340D197281Q90354656-7541EEC1-8994-4EDC-897B-3320EB2C6C5EQ90561536-10983EF7-4DA4-448D-966C-DAE46DDCC9AEQ90775023-DFED6F8F-ACD3-4EBD-A35D-336A36B984AAQ90970008-55616E63-8933-4877-A17F-599E2FA22D4C
P50
description
researcher ORCID ID = 0000-0001-8513-3758
@en
wetenschapper
@nl
name
Angelo Viscido
@ast
Angelo Viscido
@en
Angelo Viscido
@es
Angelo Viscido
@nl
type
label
Angelo Viscido
@ast
Angelo Viscido
@en
Angelo Viscido
@es
Angelo Viscido
@nl
prefLabel
Angelo Viscido
@ast
Angelo Viscido
@en
Angelo Viscido
@es
Angelo Viscido
@nl
P106
P1153
7003463128
P21
P31
P496
0000-0001-8513-3758